Introduction
============

Prostate cancer (PCa) represents the second most common cancer and the fifth most common cause of cancer-related death in men, with more than 900,000 new cases diagnosed each year [@B1]. In China, the incidence has increased by nearly six-fold during last 30 years [@B2]. Genetic risk is one of the most important factors causing PCa, which can explain \~42% of the disease carcinogenesis [@B3]. Till now, more than 100 PCa risk-associated single nucleotide polymorphisms (SNPs) have been found through genome-wide association studies (GWAS) [@B4]. However, a study showed these risk-associated SNPs could only explain about 33% of the familial risk for PCa [@B5]. In addition, most of these SNPs are located in intergenic regions [@B4]. Thus, it is hard to understand the possible functional effects of these SNPs on pathogenesis.

Copy-number variations (CNVs) are considered another major fact of genetic diversity, which could directly modulate cellular biological functions [@B6]. In addition, studies showed that CNVs cover \~35% of the human genome, while SNPs only account for less than 1% [@B7]. Several studies indicated that germline CNVs were associated with PCa in Caucasian and African-American populations [@B8]-[@B12]. However, the association between PCa and CNVs in a genome-wide level has not been reported in Chinese population.

In the present study, we performed a genome-wide CNV association study with PCa in a Chinese population by using the published GWAS data from our previous study [@B13]. Our objective was to identify possible germline PCa-risk CNV regions, which might provide additional insight to the inherited risk of PCa.

Materials and Methods
=====================

Study population
----------------

The study population is a part of Chinese Consortium for Prostate Cancer Genetics (ChinaPCa). The demographic characteristics and clinical features of the study were reported in our previous study [@B13]. All the subjects are male Han Chinese from the southeastern region of China. A total of 1,417 PCa cases and 1,008 controls were recruited. All of the cases were pathologically diagnosed with primary PCa. Controls were recruited from the community population. Written informed consent was obtained from each participant. The study was approved by the institutional review board of each medical center that participated in ChinaPCa.

Genotyping
----------

DNA was extracted from blood sample of each subject. Illumina Human OmniExpress BeadChips (Illumina, San Diego, California) were used to genotype the samples. Finally, a total of 731,458 SNPs were genotyped. Genotyping was performed at State Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai, China.

CNV Calling
-----------

Raw signal intensity files were first generated by the export function provided in Illumina GenomeStudio. Then we used UCSC Genome Browser\'s liftover tool to map SNPs to the newer reference genome assembly (<http://genome.ucsc.edu/cgi-bin/hgLiftOver>). By choosing proper population frequency of B allele (PFB) and GCmodel files, we then used PennCNV to identify CNVs and generate a quality control summary for each sample [@B14].

Quality Controls
----------------

During SNP genotyping, samples were removed if they (i) had an overall genotyping rate of \<95%; or (ii) were duplicates or showed familial relationships (PI_HAT \> 0.025). SNPs were excluded if they had (i) a call rate of \<95%; (ii) a minor allele frequency (MAF) of \<0.01; or (iii) P \< 1 × 10^-3^ in a Hardy-Weinberg equilibrium test among controls. During individual quality control analysis, samples with highly variable signal intensity was removed, including (i) LRR_SD (standard deviation of Log R Ratio) \>0.3; (ii) BAF_drift (measuring departure of the B Allele Frequency from the expected values) \> 0.01; (iii) WF (waviness factor, the amount of dispersion in signal intensity) \>0.05 or WF\<-0.05; (iv) Number of CNVs \>50 (number of called-CNVs). After individual quality control, a total of 753 cases and 982 controls with 51788 CNVs remained.

During CNV calling, CNVs were removed if (i) number of SNPs spanning less than 10; (ii) length of CNV \>50 kb. After call-level quality control, 8352 CNVs remained.

Then we merged adjacent CNV calls using a threshold of gap\<20% of total length during which 91 paired CNV were merged.

We also removed the CNVs calls located in certain regions, including HLA regions, immunoglobulin regions, telomere regions, centromere regions. After quality control analysis, a total of 6932 CNV regions were able to be used for further analyses.

Statistical Analysis
--------------------

Predicted CNVs from the sample genomic locus can have various start and end points across individuals. To make the analysis simpler, we divided the genome into copy number polymorphic regions (CNPRs). Each individuals is then assigned a copy number (CN) state for each CNPR according to the CNV predicted in that region, with CN = 2 if no CNV is predicted.[@B14] In order to discriminate the CNV with a single duplication of one allele and single deletion of the other (CN=2) from non-CNV status (CN=2), we further encoded CN state with deletion and duplication variables.[@B14] P-link 1.09 was used to perform association analysis. Logistic regression analysis was used to adjust for age. Fisher exact test was used if 25% of cells with expected count less than 5. Two-tail Bonferroni corrected *p* value of 7.2×10^-6^ (0.05/6932) was considered statistical significant.

Bioinformatics analyses
-----------------------

The CNVs found in this study were compared with the data based on normal populations in the Datablse of Genomic Variants (DGV, <http://dgv.tcag.ca/dgv/app/home>). Gene annotation in the CNV regions was performed by using UCSC gene browser. DAVID was used to perform functional annotation of affected genes located within CNVs [@B15].

Results
=======

After quality control, a total of 753 cases (PCa patients) and 982 controls were available for further analyses. The characteristics of the study population are shown in **Table [1](#T1){ref-type="table"}**. The mean age of case group was significantly higher than that of control group. The difference of age was adjusted in the further association analyses.

Seven risk-associated CNVs were identified for PCa after association analyses (*P* value in bold\<7.2×10^-6^). Another 34 CNVs were found to be potentially risk-associated CNVs (*P*\<0.05) (**Table [2](#T2){ref-type="table"}**). After comparing with DGV database, all CNV regions were previously reported overlapped with common CNVs. Among the total 41 CNVs, 27 CNVs were risk variations and the rest 14 were found to be protective variations of PCa. In addition, 25 of the CNVs (19 duplications and 6 deletions) were significantly associated with PCa and were located in gene regions (all *P* values\<0.05). The remaining 16 CNVs (9 duplications and 7 deletions) were located in intergenic regions.

In order to analyze the global burden of risk CNVs in PCa patients, we compared the amount of patients harboring different types of risk CNVs with respect to 982 controls **(Table [3](#T3){ref-type="table"})**. Risk CNVs were found in 51.5% of the PCa patients compared to 12.5% found in controls (*P* value=1.1×10^-68^). When the frequencies of deletions and duplications were analyzed separately, they were still higher in PCa patients than that in controls (9.3% vs. 2.9% in deletions with a *P* value = 8.2×10^-9^ and 46.5% vs. 10.3% in duplications with a *P* value = 1.1×10^-68^). Similar analysis was also performed in comparing the frequencies of the 14 protective CNVs in PCa patients versus in controls **(Table [3](#T3){ref-type="table"})**. Lower frequencies of the protective CNVs were observed in PCa cases for deletions, duplications and all CNVs, respectively.

Furthermore, we calculated *P* values for each CNVs and scores resulting from -log~10~ (P) are displayed in the genome-wide Manhattan plot in **Figure [1](#F1){ref-type="fig"}**. Genes located within or nearby the CNV regions were also used to perform network analysis through cBioportal using 491 TCGA prostate cancer data (Supplementary Figure [1](#SM0){ref-type="supplementary-material"}). *HLA-DRB1*, *HLA-DRB5* and *GRM5* were clinical actionable genes, among which *GRM5* was located at CNV regions and that duplication reached a genome-wide significance in our data. Since the target therapy medications (2-Methyl-6-(phenylethynyl) pyridine, MPEP) toward *GRM5* have not been approved by Food and Drug Administration (FDA), our results suggested additional evidence for its potential value as a candidate target therapy for PCa.

Discussion
==========

Studies have found several germline CNVs in Caucasian population (deletion at 2p24.3, 12q21.31, 15q21.3 and 20p13) and in African-American population (14q32.33) associated with predisposition of PCa [@B8], [@B11], [@B16], [@B17]. However, PCa risk-associated CNVs have not been reported in Chinese population. To our knowledge, this is the first genome-wide association study between CNV and PCa in Chinese population by using the published GWAS data from our previous study.

We found 41 CNVs were significantly associated with PCa and these CNVs conferring either risk or protection to PCa. More than half of the PCa risk-associated CNVs were located in gene regions. We used DAVID Bioinformatics Resources 6.8 to perform functional annotation and found that the genes were related with multiple biological processes, cellular components and molecular functions (e.g. protein binding, DNA binding, transferase activity, G-protein coupled receptor activity, virus receptor activity, hydrolase activity, nucleotide binding and so on).

For instance, in the present study, we observed a significant association between 11q14.3 duplication with PCa.*GRM5* located in 11q14.3 known as metabotropic glutamate receptor 5 is a G~q~ protein-coupled receptor that is widely expressed in the brain and activate PLCβ, resulting in intracellular Ca^2+^ release and protein kinase C (PKC) activation [@B18]. It was reported that this pathway might relate to the proliferation and migration of tumor cells which included melanoma, oral squamous cell carcinoma, nasopharyngeal carcinoma, breast cancer, colon cancer, sarcoma and various kinds of neurologic tumors. In addition, such biological effect could be inhibited by glutamate antagonists (MPEP) [@B19]-[@B27]. However, it had not been reported in prostate cancer. We also looked into the expression of *GRM5* in prostate cancer cell lines in Cancer Cell Line Encyclopedia (CCLE) and found the mRNA expression level was 4.14-4.43 (robust multi-array normalized) among 7 different prostate cancer cell lines, while the expression of *GRM5* was nearly 0 in normal prostate tissues in Genotype-Tissue Expression (GTEx) database. In the present study, the frequency of the duplication located in *GRM5* region was 13.7% in cases while the frequency was much lower in controls (1.1%). Thus we hypothesized that germline CNV of 11q14.3 may influence the expression of *GRM5* and lead to carcinogenesis of PCa. However, the function of *GRM5* related CNV increasing PCa risk and the differences between germline and somatic variations of *GRM5* should be further investigated.

Higher frequencies of specific prostate cancer risk-associated deletions and duplications had been reported in previous studies [@B8], [@B12]. Our results also revealed a relevant contribution of CNVs to PCa-risk with a higher burden of risk CNVs and a lower frequency of protective CNVs in cases compared to controls (all P values \<0.05). This provided a genome-wide summary of CNV frequencies in PCa patients and controls which might be helpful to illustrate the importance of CNVs in prostate cancer.

This case-control study was the first genome-wide CNV association study in Chinese population evaluating the relationship between CNVs and PCa. In this study, we analyzed CNV information from GWAS array by using a well-established method. Although, we failed to perform the confirmation evaluation of these CNVs at this stage, we were able to compare our findings with databases by using bioinformatics methods, and we agreed that additional validation studies should be conducted in the future. Moreover, functional studies would be necessary to validate the findings of the association between CNVs and PCa. Nevertheless, our study has provided additional information of carcinogenesis and potential treatment targets of prostate cancer.

Conclusion
==========

41 CNVs were found associated or potentially associated with PCa in the Chinese population. These results provided additional information of genetic risks of PCa. Several CNV regions involved clinical actionable genes that might be potentially targeted by medications. Additional validation and functional studies are still warranted for these results.
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###### 

Characteristics of the study population

  Variables                      Case (N=753)      Control (N=982)   P
  ------------------------------ ----------------- ----------------- --------------
  Age (year, mean±SD)^\*^        71.4±8.04         61.5±9.5          \<1.0×10^-4^
  PSA (ng/mL, median, IQR)^\*^   26.6(13.2-79.1)   0.6(0.3-1.2)      \<1.0×10^-4^
  Gleason Score (No., %)                                             
  \<7                            189(25.1)         \-                
  ≥7                             500(66.4)         \-                
  Missing                        64(8.5)           \-                

^\*^Age and PSA at diagnosis for cases or at recruitment for controls.

###### 

Copy number variations associated with prostate cancer in potential

  Chr.   Start       End         CNV type   Direction    Cases   Control   OR      *P* value          Genes
  ------ ----------- ----------- ---------- ------------ ------- --------- ------- ------------------ ------------------------------------------------
  19     20079177    21077133    Del        risk         9       0         12.60   2.39×10^-3^        ^\*^CR593334,CR614976,LOC284441,ZNF430,ZNF486
  11     67258202    67488532    Del        risk         32      2         2.08    6.77×10^-3^        AK091996,BC110365,CR602694
  10     59242376    59438056    Del        risk         9       0         6.30    1.08×10^-2^        intergenic
  21     20315468    20449022    Del        risk         5       0         INF     1.27×10^-2^        intergenic
  11     88204734    88263638    Del        risk         4       0         INF     3.03×10^-2^        GRM5
  16     2136084     2187363     Del        risk         4       0         INF     3.03×10^-2^        CASKIN1,RAB26,SNORD60,TRAF7
  16     616990      718025      Del        risk         4       0         INF     3.03×10^-2^        ^\*^AK128777,AL360260,C16orf13,C16orf14,CCDC78
  3      4132503     4187007     Del        risk         7       0         4.89    3.98×10^-2^        SUMF1
  6      79031809    79086086    Dup        risk         157     33        7.02    **7.86×10^-32^**   intergenic
  11     88336310    88384073    Dup        risk         103     11        13.72   **2.39×10^-28^**   GRM5
  18     14737958    14828909    Dup        risk         45      17        3.74    **9.08×10^-7^**    ANKRD30B
  6      32601768    32664508    Dup        risk         19      3         8.90    2.71×10^-5^        AK293020,HLA-DRB1,HLA-DRB5
  10     22249227    22376157    Dup        risk         11      0         INF     6.63×10^-5^        DNAJC1
  15     19257404    19408394    Dup        risk         6       0         INF     5.28×10^-3^        A26B1,DQ582260,M84131,POTEB
  6      80285260    80386902    Dup        risk         6       0         INF     5.28×10^-3^        LCA5
  4      9003188     9169160     Dup        risk         11      3         5.13    6.25×10^-3^        DEFB131,LOC650293
  5      109845447   109992561   Dup        risk         7       1         9.79    1.12×10^-2^        FLJ43080
  5      32143138    32144121    Dup        risk         32      22        2.04    1.19×10^-2^        KIAA0300,PDZD2
  13     63130342    63185384    Dup        risk         5       0         INF     1.26×10^-2^        intergenic
  16     32073040    32556470    Dup        risk         5       0         INF     1.27×10^-2^        BC041879,BC042588,DQ571479,TP53TG3b,X69637
  11     58563817    58634485    Dup        risk         19      12        2.22    2.93×10^-2^        AX746988,FAM111B
  12     85219842    85281435    Dup        risk         4       0         INF     3.03×10^-2^        MGAT4C
  18     12062364    12122247    Dup        risk         4       0         INF     3.03×10^-2^        BX648696,BX649021
  3      76005745    76061858    Dup        risk         4       0         INF     3.03×10^-2^        intergenic
  10     6717773     6783787     Dup        risk         7       2         4.89    3.98×10^-2^        intergenic
  1      149608041   149614444   Dup        risk         7       2         4.89    3.98×10^-2^        SELENBP1
  7      61631605    61631605    Dup        risk         45      17        3.74    **9.08×10^-7^**    intergenic
  19     32620453    32675491    Del        protective   50      421       0.15    **8.96×10^-54^**   intergenic
  11     50432844    50586426    Del        protective   34      179       0.25    **2.54×10^-16^**   intergenic
  12     36785447    36801139    Del        protective   7       43        0.22    3.47×10^-5^        intergenic
  19     24228244    24354405    Del        protective   5       26        0.27    3.13×10^-3^        intergenic
  9      11941222    12175185    Del        protective   3       15        0.28    3.20×10^-2^        intergenic
  5      99455964    99486169    Dup        protective   1       32        0.04    **8.23×10^-7^**    intergenic
  8      145079175   145131413   Dup        protective   3       29        0.14    9.22×10^-5^        PARP10,PLEC1
  8      114044747   114181033   Dup        protective   17      57        0.41    8.19×10^-4^        CSMD3
  1      187833278   187886901   Dup        protective   2       17        0.16    4.59×10^-3^        intergenic
  4      162057165   162075793   Dup        protective   27      64        0.58    1.85×10^-2^        intergenic
  12     22509872    22573948    Dup        protective   0       8         0.00    2.44×10^-2^        KIAA0528
  19     21936987    21995054    Dup        protective   0       8         0.00    2.44×10^-2^        ZFS-3,ZNF208
  4      145164558   145169643   Dup        protective   2       13        0.21    3.31×10^-2^        GYPA
  7      53164643    53216869    Dup        protective   0       7         0.00    4.64×10^-2^        intergenic

*P* values and ORs are from a regional test at each locus. INF, infinite; Del, deletion; Dup, duplication. ^\*^Only five genes in that region were listed.

###### 

Comparisons of the frequencies of risk and protective copy number variations detected in the cases and controls

  Group                 Cases(n=753)   Controls(n=982)   *P* value
  --------------------- -------------- ----------------- -----------
  Risk CNVs, N          27             14                
  Deletions, n (%)      70(9.3%)       28(2.9%)          8.24E-09
  Duplications, n (%)   350(46.5%)     101(10.3%)        4.38E-65
  All CNVs, n (%)       385(51.5%)     123(12.5%)        1.13E-68
  Protective CNVs, N    11             14                
  Deletions, n (%)      70(9.3%)       512(52.1%)        2.68E-78
  Duplications, n (%)   51(6.8%)       208(21.2%)        7.01E-17
  All CNVs, n (%)       118(15.7%)     626(63.7%)        1.84E-89

*P* values were calculated by Chi-test; N, number of CNVs; n, number of patients harboring CNVs.
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